Goldman Sachs initiated coverage of Boston Scientific with a Buy rating and $90 price target. The company is entering a multi-year period of new product launches and is further shifting its end market exposure to higher growth segments, the analyst tells investors in a research note. The firm says Boston Scientific’s sustained reinvestment into the business will drive further competitive differentiation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $95 from $80 at Argus
- Boston Scientific participates in a conference call with JPMorgan
- Boston Scientific price target raised to $87 from $85 at Citi
- Boston Scientific price target raised to $90 from $85 at Mizuho
- Boston Scientific Welcomes New Director and Updates Governance